Calamos Advisors LLC Purchases 677,341 Shares of Pfizer Inc. (NYSE:PFE)

Calamos Advisors LLC increased its position in Pfizer Inc. (NYSE:PFE) by 70.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,642,574 shares of the biopharmaceutical company’s stock after acquiring an additional 677,341 shares during the period. Calamos Advisors LLC’s holdings in Pfizer were worth $43,577,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Matisse Capital purchased a new position in shares of Pfizer during the 4th quarter valued at $202,000. Alliance Wealth Advisors LLC UT boosted its stake in shares of Pfizer by 5.6% in the fourth quarter. Alliance Wealth Advisors LLC UT now owns 12,571 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 669 shares during the period. Vantage Point Financial LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $485,000. Holistic Planning LLC raised its stake in Pfizer by 11.2% during the 4th quarter. Holistic Planning LLC now owns 51,573 shares of the biopharmaceutical company’s stock valued at $1,368,000 after purchasing an additional 5,209 shares during the period. Finally, Lazari Capital Management Inc. grew its position in shares of Pfizer by 45.0% during the fourth quarter. Lazari Capital Management Inc. now owns 32,229 shares of the biopharmaceutical company’s stock valued at $855,000 after purchasing an additional 10,005 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.23 on Tuesday. The firm has a market capitalization of $148.62 billion, a P/E ratio of 35.44, a P/E/G ratio of 0.66 and a beta of 0.64. The company has a fifty day moving average of $26.27 and a 200-day moving average of $27.85. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.56%. Pfizer’s dividend payout ratio (DPR) is 232.44%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Wolfe Research initiated coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.